

Attorney Docket No.: 5956.200-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: 09/662,457

Group Art Unit: 1626

Filed: September 11, 2000

Examiner: Robert Gerstl

Confirmation No: 9106

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

#13
Apparatus
3/17/03

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Commissioner for Patents
Box RCE
Washington, DC 20231

Sir:

This is a request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above identified application.

1. Submission required under 37 C.F. R. § 1.114

a. ☐ Previously submitted

- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on
- ii. ☐ Consider the arguments in the Appeal Brief of Reply Brief previously filed on
- iii. ☐ Other

b. ☒ Enclosed

- i. ☒ Amendment to Office Action dated August 26, 2002.
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other

2. Miscellaneous

03/05/2003 MAHME1 00000114 141447 09662457

01 FC:1801 750.00 CH

a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of _____ months. (period of suspension shall not exceed 3 months, Fee under 37 C.F.R. § 1.17 (i) required)

b. ☐ Other

3. In the event that an extension of time is required, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account 14-1447.

4. Fees The RCE fee under 37 C.F.R. § 1.17 (e) is required by 37 C.F.R. § 1.114 when the RCE is filed.


a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit **Account No. 14-1447**.

- i. ☒ RCE fee required under 37 C.F.R. § 1.17 (e) (\$750)
- ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
- iii. ☒ Other-claims fees (\$552)

Respectfully submitted,

Date:

2/26/03



Cheryl H. Agris, Reg. No. 34,086
Outside Counsel for
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540



RECEIVED
MAR 08 2003
TECH CENTER 1600/2600

Attorney Docket No.: 5956.200-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: 09/662,457

Group Art Unit: 1626

Filed: September 11, 2000

Examiner: Robert Gerstl

Confirmation No: 9106

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. RCE Transmittal (in duplicate)
2. Amendment

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on February 26, 2003.

Cheryl H. Agris
(name of person mailing paper)

Cheryl H. Agris
(signature of person mailing paper)